An experimental antibody treatment that binds to a protein known as PCDH7 shrank tumors in preclinical models of non-small cell lung cancer, even those resistant to a targeted therapy, a study led by UT Southwestern Medical Center researchers showed. This discovery could eventually lead to a new class of drugs to treat NSCLC and potentially other cancers.
A multidisciplinary team co-led by Amit Singal, chief of hepatology and director of the Liver Tumor Program in the Division of Digestive and Liver Diseases at UT Southwestern Medical Center, has developed new treatment recommendations for liver cancer that incorporate the latest research and an expanding range of therapeutic options.
